New diarylsulfonamide inhibitors of Leishmania infantum amastigotes

Abu Ammar, 2019, Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis, Drug Deliv. Transl. Res., 9, 76, 10.1007/s13346-018-00603-0 Alcolea, 2010, Transcriptomics throughout the life cycle of Leishmania infantum: high down-regulation rate in the amastigote stage, Int. J. Parasitol., 40, 1497, 10.1016/j.ijpara.2010.05.013 Alcolea, 2014, Stage-specific differential gene expression in Leishmania infantum: from the foregut of Phlebotomus perniciosus to the human phagocyte, BMC Genom., 15, 10.1186/1471-2164-15-849 Alcolea, 2016, Differential protein abundance in promastigotes of nitric oxide-sensitive and resistant Leishmania chagasi strains, Proteonomics Clin. Appl., 10, 1132, 10.1002/prca.201600054 Almeida, 2004, Expression profiling of the Leishmania life cycle: cDNA arrays identify developmentally regulated genes present but not annotated in the genome, Mol. Biochem. Parasitol., 136, 87, 10.1016/j.molbiopara.2004.03.004 Alvar, 2012, Leishmaniasis worldwide and global estimates of its incidence, PloS One, 10.1371/journal.pone.0035671 Álvarez, 2013, Endowing indole-based tubulin inhibitors with an anchor for derivatization: highly potent 3-substituted indolephenstatins and indoleisocombretastatins, J. Med. Chem., 56, 2813, 10.1021/jm3015603 Alves, 2018, Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives, Clin. Microbiol. Rev., 10.1128/CMR.00048-18 Arce, 2013 Bateman, 2019, UniProt: a worldwide hub of protein knowledge, Nucleic Acids Res., 47, D506, 10.1093/nar/gky1049 Berman, 2003, Announcing the worldwide protein Data Bank, Nat. Struct. Biol., 10.1038/nsb1203-980 Berthold, 2007, KNIME: the konstanz information miner, 319 Daina, 2017, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep., 7, 10.1038/srep42717 De Muylder, 2011, A screen against leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit, PLoS Neglected Trop. Dis., 5, 10.1371/journal.pntd.0001253 De Rycker, 2018, Challenges and recent progress in drug discovery for tropical diseases, Nature, 10.1038/s41586-018-0327-4 Dostál, 2014 Drews, 2000, Drug discovery: a historical perspective, Science, 80– Dumontet, 2010, Microtubule-binding agents: a dynamic field of cancer therapeutics, Nat. Rev. Drug Discov. Escudero-Martínez, 2017, Antileishmanial activity and tubulin polymerization inhibition of podophyllotoxin derivatives on Leishmania infantum, Int. J. Parasitol. Drugs Drug Resist., 7, 272, 10.1016/j.ijpddr.2017.06.003 Forli, 2016, Computational protein-ligand docking and virtual drug screening with the AutoDock suite, Nat. Protoc., 11, 905, 10.1038/nprot.2016.051 Furtado, 2016, Benzimidazole resistance in helminths: from problem to diagnosis, Acta Trop., 10.1016/j.actatropica.2016.06.021 Garcia-Perez, 2017, JADOPPT: java based AutoDock preparing and processing tool, Bioinformatics, 33, 583, 10.1093/bioinformatics/btw677 Jain, 2018, Molecular targets and pathways for the treatment of visceral leishmaniasis, Drug Discov. Today, 10.1016/j.drudis.2017.09.006 Jiménez, 2014, Could wild rabbits (Oryctolagus cuniculus) be reservoirs for Leishmania infantum in the focus of Madrid, Spain?, Vet. Parasitol., 202, 296, 10.1016/j.vetpar.2014.03.027 Jordan, 1998, Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle, Med. Res. Rev., 18, 259, 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.0.CO;2-U Korb, 2009, Empirical scoring functions for advanced Protein-Ligand docking with PLANTS, J. Chem. Inf. Model., 49, 84, 10.1021/ci800298z Lacey, 1990, Mode of action of benzimidazoles, Parasitol. Today, 6, 112, 10.1016/0169-4758(90)90227-U Larkin, 2007, Clustal W and clustal X version 2.0, Bioinformatics, 23, 2947, 10.1093/bioinformatics/btm404 Laurence, 2009, The pKBHX database: toward a better understanding of hydrogen-bond basicity for medicinal chemists, J. Med. Chem., 10.1021/jm801331y Légaré, 2001, The leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase, J. Biol. Chem., 276, 26301, 10.1074/jbc.M102351200 Leifso, 2007, Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: the Leishmania genome is constitutively expressed, Mol. Biochem. Parasitol., 152, 35, 10.1016/j.molbiopara.2006.11.009 Luis, 2013, Comparative analyses of the β-tubulin gene and molecular modeling reveal molecular insight into the colchicine resistance in kinetoplastids organisms, BioMed Res. Int., 843748 Marquis, 2005, Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania, Mol. Microbiol., 57, 1690, 10.1111/j.1365-2958.2005.04782.x Marvin, 2017, vol. 8 Massarotti, 2012, The tubulin colchicine domain: a molecular modeling perspective, ChemMedChem, 10.1002/cmdc.201100361 Mbongo, 1998, Mechanism of amphotericin B resistance in Leishmania donovani promastigotes, Antimicrob. Agents Chemother., 42, 352, 10.1128/AAC.42.2.352 Molina, 2012, The hare (Lepus granatensis) as potential sylvatic reservoir of Leishmania infantum in Spain, Vet. Parasitol., 190, 268, 10.1016/j.vetpar.2012.05.006 Mondelaers, 2016, Genomic and molecular characterization of miltefosine resistance in leishmania infantum strains with either natural or acquired resistance through experimental selection of intracellular amastigotes, PloS One, 11, 10.1371/journal.pone.0154101 Montecinos-Franjola, 2019, All tubulins are not alike: heterodimer dissociation differs among different biological sources, J. Biol. Chem., 294, 10315, 10.1074/jbc.RA119.007973 Monzote, 2009, Current treatment of leishmaniasis: a review, Open Antimicrob. Agents J. Nagle, 2014, Recent developments in drug discovery for leishmaniasis and human african trypanosomiasis, Chem. Rev., 10.1021/cr500365f OpenEye Scientific Software, 2019 Pérez-Victoria, 2003, Functional cloning of the miltefosine transporter: a novel p-type phospholipid translocase from leishmania involved in drug resistance, J. Biol. Chem., 278, 49965, 10.1074/jbc.M308352200 Pérez-Victoria, 2006, Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use, Drug Resist. Updates, 9, 26, 10.1016/j.drup.2006.04.001 Perlovich, 2014, Impact of sulfonamide structure on solubility and transfer processes in biologically relevant solvents, J. Chem. Eng. Data, 59, 4217, 10.1021/je500918t Pettersen, 2004, UCSF Chimera-A visualization system for exploratory research and analysis, J. Comput. Chem., 25, 1605, 10.1002/jcc.20084 Ponte-Sucre, 2017, Drug resistance and treatment failure in leishmaniasis: a 21st century challenge, PLoS Neglected Trop. Dis., 10.1371/journal.pntd.0006052 Rama, 2015, A comprehensive review of patented antileishmanial agents, Pharm. Pat. Anal., 10.4155/ppa.14.55 Rijal, 2013, Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance, Clin. Infect. Dis., 56, 1530, 10.1093/cid/cit102 Rochette, 2009, Whole-genome comparative RNA expression profiling of axenic and intracellular amastigote forms of Leishmania infantum, Mol. Biochem. Parasitol., 165, 32, 10.1016/j.molbiopara.2008.12.012 Šali, 1993, Comparative protein modelling by satisfaction of spatial restraints, J. Mol. Biol., 234, 779, 10.1006/jmbi.1993.1626 Scudiero, 1988, Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines, Canc. Res., 48, 4827 Sinclair, 2019, More than microtubules: the structure and function of the subpellicular array in trypanosomatids, Trends Parasitol., 10.1016/j.pt.2019.07.008 Sundar, 2002, Oral miltefosine for Indian visceral leishmaniasis, N. Engl. J. Med., 347, 1739, 10.1056/NEJMoa021556 Sundar, 2007, Injectable paromomycin for visceral leishmaniasis in India, N. Engl. J. Med., 356, 2571, 10.1056/NEJMoa066536 Sundar, 2005, Availability of miltefosine for the treatment of kala-azar in India, Bull. World Health Organ., 83, 394 Sunter, 2017, Shape, form, function and Leishmania pathogenicity: from textbook descriptions to biological understanding, Open Biol, 10.1098/rsob.170165 Tiuman, 2011, Recent advances in leishmaniasis treatment, Int. J. Infect. Dis., 10.1016/j.ijid.2011.03.021 Vandermeulen, 2006, Encapsulation of amphotericin B in poly(ethylene glycol)-block-poly(ε- caprolactone-co-trimethylenecarbonate) polymeric micelles, Int. J. Pharm., 309, 234, 10.1016/j.ijpharm.2005.11.031 Vicente‐Blázquez, 2019, Antitubulin sulfonamides: the successful combination of an established drug class and a multifaceted target, Med. Res. Rev., 39, 775, 10.1002/med.21541 Zhang, 2018, Synthesis, characterization, and antileishmanial activity of neutral N-heterocyclic carbenes gold(I) complexes, Eur. J. Med. Chem., 143, 1635, 10.1016/j.ejmech.2017.10.060 Zulfiqar, 2017, Leishmaniasis drug discovery: recent progress and challenges in assay development, Drug Discov. Today, 10.1016/j.drudis.2017.06.004